MedPath

Clinical Trial News

Global Economic Pressures Force Pharmaceutical Industry to Confront Radical Transformation

  • The pharmaceutical industry faces unprecedented challenges due to patent cliffs, pricing pressures, and a shift from blockbuster drugs to niche products, necessitating fundamental industry restructuring.
  • Healthcare systems, particularly in the UK and US, are implementing severe cost-cutting measures, with the NHS targeting £20bn in annual savings and US healthcare requiring $80bn reduction over 10 years.
  • Industry experts call for urgent reform of regulatory frameworks, including Good Clinical Practice guidelines and EU Clinical Trials directive, to maintain pharmaceutical innovation while managing rising development costs.

FDA Expands Access to Investigational Drugs for Treatment Use

The FDA has finalized a rule to expand access to investigational drugs for patients with serious or immediately life-threatening diseases or conditions who have no comparable or satisfactory alternative therapy. This rule aims to increase awareness and knowledge of expanded access programs, detailing criteria, submission requirements, and safeguards for different types of expanded access.

NZ Scientist's Gene Research Offers Hope Against Obesity Epidemic

A New Zealand researcher, Professor Matthew During, is pioneering gene therapy to combat obesity, following successful animal trials. The therapy targets the brain's hypothalamus to regulate weight and could enter human clinical trials within a year.

FDA Issues Guidance for Cardiovascular Risk Assessment of Novel Antidiabetic Agents

The FDA has released final guidance for assessing cardiovascular risks in new type 2 diabetes treatments, emphasizing the importance of clinical trials to ensure these therapies do not increase cardiovascular event risks. The guidance mandates detailed safety information from Phase II and III trials, including the establishment of a cardiovascular end-point committee and the inclusion of high-risk individuals. A meta-analysis of trial data is required post-trial to evaluate drug safety comprehensively.

WuXi PharmaTech Strengthens Board with Strategic Appointments of Industry Veterans

• WuXi PharmaTech has appointed several key executives to its Board of Directors, including Ying Han, Stewart Hen, and co-founder Ning Zhao, bringing valuable financial and pharmaceutical expertise to the company.
• The strategic board appointments aim to enhance WuXi's business operations and financial systems as the company continues to expand its pharmaceutical R&D outsourcing services in China and the United States.
• Co-founder Tao Lin has stepped down from his position on the board and as Vice President of Internal Operations, marking a significant leadership transition for the growing pharmaceutical services organization.

New Cancer Treatment Successes Identified in Phase 3 Trials

A comprehensive evaluation of phase 3 randomized controlled trials (RCTs) conducted by the NCI-funded COG program from 1955 to 2000 reveals that new cancer treatments were statistically superior in 24% of comparisons, with a 5% relative reduction in the death rate. The study highlights the importance of the ethical principle of equipoise in clinical research and suggests that the current system of RCTs in cancer is efficient within certain limits, with a consistent pattern of treatment successes over time.

KU Team Announces Breakthrough in Leishmaniasis Treatment

Scientists at Karachi University's H.E.J. Research Institute of Chemistry have developed a herbal ointment for treating cutaneous leishmaniasis, showing high success rates in clinical trials without side effects. The disease, a significant public health concern in Pakistan, has seen a 90% treatment success rate in trials.

Study on Adherence to Glaucoma Medication Regimens

A study utilizing electronic monitoring to objectively measure adherence to glaucoma medication regimens found good adherence rates among patients using once-daily prostaglandin analogs, whether as sole therapy or with an adjunctive medicine.

Mifepristone Shows Promise as Weekly Contraceptive in Clinical Trial

  • A clinical trial in China evaluated weekly doses of 25mg and 50mg of mifepristone for contraception, demonstrating no pregnancies across 456 women-months of use.
  • The 50mg mifepristone group experienced significantly fewer bleeding days and more bleeding-free days compared to the 25mg group in later study cycles.
  • Side effects like nausea and breast distension were uncommon and mild in both mifepristone dosage groups, suggesting good tolerability.
  • These findings suggest weekly mifepristone could be a potential contraceptive option, warranting further investigation into its efficacy and safety.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy